Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings

被引:10
|
作者
Moridera, Kuniyasu [1 ]
Kitajima, Kazuhiro [2 ]
Yoshikawa, Kyohei [1 ]
Takaoka, Kazuki [1 ]
Tsuchitani, Tatsuya [3 ]
Noguchi, Kazuma [1 ]
Kishimoto, Hiromitsu [1 ]
Yamakado, Koichiro [2 ]
机构
[1] Hyogo Coll Med, Dept Oral & Maxillofacial Surg, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Dept Radiol, Nishinomiya, Hyogo, Japan
[3] Hyogo Coll Med Coll Hosp, Dept Radiol Technol, Nishinomiya, Hyogo, Japan
关键词
Medication-related osteonecrosis of the jaw (MRONJ); Bone SPECT; CT; SUV; Metabolic bone volume (MBV); BISPHOSPHONATE-RELATED OSTEONECROSIS; MANAGEMENT;
D O I
10.1007/s11604-021-01226-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective This study was conducted to investigate the clinical utility of quantitative bone single-photon computed tomography-computed tomography (SPECT/CT) for detection and classification for medication-related osteonecrosis of the jaw (MRONJ). Materials and methods Fifty-nine patients (69 lesions) clinically diagnosed as MRONJ by four specialists of Japanese Society of Oral Surgery according to the AAOMS diagnostic criteria and who underwent bone SPECT/CT were enrolled. One reader determined standard uptake values (SUVs), including maximum (SUVmax), peak (SUVpeak), and mean (SUVmean), as well as metabolic bone volume (MBV), representing total volume above threshold, and total bone uptake (TBU), calculated as MBV x SUVmean, using the GI-BONE software package. One-way repeated-measures analysis of variance and subsequent post hoc analysis were employed to compare quantitative values between clinical stages. To check reproducibility of values, another reader calculated these quantitative values. Results Mean SUVmax values for stage 0 (n = 21), 1 (n = 13), 2 (n = 25), and 3 (n = 10) were 5.82 +/- 3.20, 5.46 +/- 3.79, 8.16 +/- 3.93, and 10.57 +/- 8.43, respectively, while values for MBV were 9.52 +/- 6.33, 11.36 +/- 7.32, 12.4 +/- 8.21, and 17.84 +/- 16.94, respectively, and for TBU were 40.60 +/- 46.97, 53.70 +/- 77.26, 62.37 +/- 42.91, and 102.01 +/- 74.52, respectively. There were significant differences for SUVmax, SUVpeak, and SUVmean between clinical stages (p = 0.024, p = 0.027, p = 0.039, respectively). Subsequent post hoc analysis showed that SUVmax and SUVpeak of stage 3 were significantly higher than those of stage 0 (p = 0.046, 0.045, respectively). MBV and TBU showed a tendency to increase with increased stage, though differences between stages were not significant (p = 0.15, p = 0.053, respectively). Little differences of mean SUVmax, SUVpeak, SUVmean, MBV, and TBU between two readers were observed (- 3.10%, - 0.26%, - 4.24%%, 0.69%, and - 3.42%, respectively). The intraclass correlation coefficients (ICCs) of SUVmax, SUVpeak, SUVmean, MBV, and TBU were 0.985, 0.990, 0.980, 0.994, and 0.994, respectively (almost perfect for all values). Conclusion As objective and reliable indicators, SUVmax and SUVpeak derived from quantitative bone SPECT/CT results are useful for detection of early status disease, as well as staging in MRONJ patients.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 50 条
  • [21] Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value
    Ogawa, Ruri
    Ogura, Ichiro
    DENTOMAXILLOFACIAL RADIOLOGY, 2021, 50 (08)
  • [22] Bacterial diversity in medication-related osteonecrosis of the jaw
    Hallmer, Fredrik
    Bjornland, Tore
    Andersson, Gunilla
    Becktor, Jonas P.
    Kristoffersen, Anne K.
    Enersen, Morten
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2017, 123 (04): : 436 - 444
  • [23] Severe Maxillary Medication-related Osteonecrosis of the Jaw
    Kitajima, Shoichiro
    Mizuno, Susumu
    Kogiso, Ryo
    Tsuji, Chiaki
    INTERNAL MEDICINE, 2018, 57 (22) : 3341 - 3341
  • [24] Mechanisms Underlying Medication-Related Osteonecrosis of the Jaw
    Lee, Kyeongho
    Kim, Kihun
    Kim, June Yeon
    Kim, Jin-Woo
    Kang, Young-Hoon
    Kim, Yun Hak
    Kim, Sung-Jin
    ORAL DISEASES, 2024,
  • [25] Medication-related osteonecrosis of the jaw - Personal comments
    Pitak-Arnnop, Poramate
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2018, 39 (06) : 802 - 802
  • [26] Interventions for managing medication-related osteonecrosis of the jaw
    Beth-Tasdogan, Natalie H.
    Mayer, Benjamin
    Hussein, Heba
    Zolk, Oliver
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
  • [27] Medication-related osteonecrosis of the jaw: A literature review
    Kuroshima, Shinichiro
    Sasaki, Muneteru
    Sawase, Takashi
    JOURNAL OF ORAL BIOSCIENCES, 2019, 61 (02) : 99 - 104
  • [28] Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw
    Roato, Ilaria
    Mauceri, Rodolfo
    Notaro, Vincenzo
    Genova, Tullio
    Fusco, Vittorio
    Mussano, Federico
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [29] Prognostic factors of the medication-related osteonecrosis of the jaw
    Szentpeteri Szofia
    Restar Laszlo
    Nemeth Zsolt
    Vaszilko Mihaly
    ORVOSI HETILAP, 2020, 161 (08) : 283 - 289
  • [30] Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review
    Muecke, Thomas
    Krestan, Christian R.
    Mitchell, David A.
    Kirschke, Jan S.
    Wutzl, Arno
    SEMINARS IN MUSCULOSKELETAL RADIOLOGY, 2016, 20 (03) : 305 - 314